Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(17%)
Results Posted
50%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
1
17%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

completed467%
terminated117%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT03223610
completed

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

NCT03106324
completedphase_2

Revlimid in Transfusion Dependent Patients

NCT01178814
terminated

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

NCT01947309
completedphase_1

Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma

NCT00778752
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03223610Phase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Recruiting
NCT03106324

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Completed
NCT01178814Phase 2

Revlimid in Transfusion Dependent Patients

Completed
NCT01947309

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

Terminated
NCT00778752Phase 1

Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma

Completed
NCT00507442Phase 1

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6